How Amgen uses GPT-5
Summary
Amgen, a major pharmaceutical company, shares how it leverages GPT-5 in its operations. The case study highlights enterprise adoption of advanced AI models in the biotech/pharma sector.
View Cached Full Text
Cached at: 04/20/26, 02:43 PM
Similar Articles
Genmab launches “AI Everywhere”
Genmab, a biotechnology company, launches "AI Everywhere" initiative to deploy ChatGPT Enterprise across 2,000+ employees, reporting average time savings of 3.5 hours per week and enabling new capabilities like advanced document analysis and clinical trial automation through GPT-4o.
Medical research with GPT-5
OpenAI announces the application of GPT-5 to medical research, highlighting the model's capabilities in healthcare and scientific discovery domains.
Measuring AI’s capability to accelerate biological research
OpenAI demonstrates GPT-5's capability to accelerate biological research by autonomously optimizing a molecular cloning protocol in collaboration with Red Queen Bio, achieving a 79-fold improvement in cloning efficiency through novel enzymatic mechanisms. The work showcases AI's potential to support experimental iteration and empirical validation in wet lab settings while highlighting biosecurity considerations.
Accelerating life sciences research
OpenAI collaborated with Retro Biosciences to develop GPT-4b micro, a specialized version of GPT-4o for protein engineering, achieving 50-fold higher expression of stem cell reprogramming markers with enhanced DNA damage repair capabilities. The findings have been validated across multiple donors and cell types, demonstrating AI's potential to accelerate life sciences research.
Inside GPT-5 for Work: How Businesses Use GPT-5
OpenAI releases a comprehensive report analyzing ChatGPT adoption patterns in the workplace, revealing that 28% of employed adults use ChatGPT at work (up from 8% two years ago) and 43% of U.S. knowledge workers use AI tools, with significant productivity gains and demographic variations in adoption.